NCT01583218 2023-08-07APEXAlexion Pharmaceuticals, Inc.Phase 3 Completed7,513 enrolled 18 charts 1 FDA
NCT02555878 2019-09-12A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsJanssen Research & Development, LLCPhase 3 Completed841 enrolled 24 charts
NCT00952380 2019-04-16Fragmin for the Treatment of Acute VTE in Pediatric Cancer PatientsPfizerPhase 2 Completed38 enrolled 30 charts
NCT02073682 2019-03-06Cancer Venous Thromboembolism (VTE)Daiichi SankyoPhase 3 Completed1,046 enrolled 24 charts